Skip to main content

Table 2 Univariate and multivariate analyses about survival outcomes in the patients treated with S-1

From: Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study

Characteristics

 

Number of patients (%)

Unadjusted HR (95% CI)

P Value

Adjusted HR (95% CI)

P Value

Total

13,614 (100.0)

    

Age, years

 < 30

53 (0.4)

1

 

1

 

30–39

447 (3.3)

0.71 (0.41–1.21)

0.207

0.69 (0.40–1.18)

0.172

40–49

1,417 (10.4)

0.54 (0.32–0.91)

0.021

0.53 (0.31–0.89)

0.016

50–59

2,980 (21.9)

0.61 (0.36–1.01)

0.057

0.57 (0.34–0.95)

0.032

60–69

3,759 (27.6)

0.76 (0.46–1.27)

0.294

0.70 (0.42–1.17)

0.173

70–79

4,166 (30.6)

1.18 (0.71–1.96)

0.528

0.95 (0.57–1.58)

0.834

 ≥ 80

792 (5.8)

2.10 (1.25–3.53)

0.005

1.44 (0.85–2.43)

0.175

Gender

Male

9,226 (67.8)

1

 

1

 

Female

4,388 (32.2)

0.86 (0.80–0.93)

0.0002

0.83 (0.77–0.90)

 < 0.0001

Comorbidities

DM

No

10,254 (75.3)

1

 

1

 

Yes

3,360 (24.7)

1.25 (1.16–1.36)

 < 0.0001

1.11 (1.01–1.21)

0.03

Hypertension

No

7,811 (57.4)

1

 

1

 

Yes

5,803 (42.6)

1.16 (1.08–1.25)

 < 0.0001

0.89 (0.82–0.96)

0.004

Dyslipidemia

No

9,079 (66.7)

1

 

1

 

Yes

4,535 (33.3)

1.04 (0.97–1.13)

0.292

0.96 (0.88–1.05)

0.375

COPD

No

12,053 (88.5)

1

 

1

 

Yes

1,561 (11.5)

1.19 (1.07–1.33)

0.002

0.99 (0.89–1.10)

0.839

Chemotherapy cycles

 ≥ 8 cycles

6,930 (50.9)

1

 

1

 

7 < cycles < 8

1,071 (7.9)

1.60 (1.39–1.84)

 < 0.0001

1.54 (1.34–1.78)

 < 0.0001

6 < cycles ≤ 7

990 (7.3)

2.11 (1.84–2.41)

 < 0.0001

2.03 (1.78–2.32)

 < 0.0001

5 < cycles ≤ 6

709 (5.2)

3.08 (2.65–3.57)

 < 0.0001

2.86 (2.47–3.32)

 < 0.0001

 ≤ 5 cycles

3,914 (28.7)

4.06 (3.74–4.40)

 < 0.0001

3.64 (3.35–3.95)

 < 0.0001

  1. Abbreviations: HR Hazard ratio, CI Confidence interval, DM Diabetes mellitus, COPD Chronic obstructive pulmonary disease